Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month [Yahoo! Finance]
Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Moderna (NasdaqGS:MRNA) Up 11% Despite Patent Lawsuit Challenges [Yahoo! Finance]